JPS58208233A - Formulating ingredient for treating peptic ulcer - Google Patents
Formulating ingredient for treating peptic ulcerInfo
- Publication number
- JPS58208233A JPS58208233A JP9141382A JP9141382A JPS58208233A JP S58208233 A JPS58208233 A JP S58208233A JP 9141382 A JP9141382 A JP 9141382A JP 9141382 A JP9141382 A JP 9141382A JP S58208233 A JPS58208233 A JP S58208233A
- Authority
- JP
- Japan
- Prior art keywords
- sucralfate
- ulcer
- aldioxa
- treating
- formulating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
【発明の詳細な説明】
本発明はアルジオキサ及びスクラルファートを配合した
消化性潰瘍治療配合剤に関する。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a combination for the treatment of peptic ulcers containing ardioxa and sucralfate.
消化性潰瘍の成因は必らずしも一元的には解釈されずい
くつかの因子が密接に関連し合って発生すると考えられ
ており、胃液の酸およびペプシンを中心とする攻撃因子
と消化管粘膜の防御因子のバランスの破綻で説明されて
いる。The etiology of peptic ulcers cannot necessarily be interpreted uniformly; it is thought that several factors are closely related to each other. It is explained by the disruption of the balance of mucosal protective factors.
従来、消化性潰瘍の治療剤は、種々存在し、それらは上
述の潰瘍発生因子のいずれかに作用するものである0即
ち、攻撃因子の抑制を目的とした薬剤には、制酸剤、抗
ペプシン剤、抗コリン剤、抗ガストリン剤、更には最近
のものとし抗ヒスタミンH2剤があり、一方防御因子の
増強を目的とした薬剤としては消化管粘膜修復促進剤が
ある。前者の薬剤の具体的な例として、シメチジン、ス
クラルファート、ウロガストμン、水酸化アルミニウム
グル、臭化バレタメート、臭化ブチルスコポラミンが、
後者の具体的な薬剤としてはアルジオ千す、グツアルナ
ート、L−グルタミン等が挙げられる。Conventionally, there are various therapeutic agents for peptic ulcers, and they act on any of the ulcerogenic factors mentioned above.In other words, drugs aimed at suppressing the aggressive factors include antacids and anti-inflammatory drugs. There are pepsin agents, anticholinergic agents, antigastrin agents, and more recently, antihistamine H2 agents, and on the other hand, agents aimed at enhancing protective factors include gastrointestinal mucosal repair promoters. Specific examples of the former drugs include cimetidine, sucralfate, urogastone, aluminum hydroxide, valetamate bromide, and butyl scopolamine bromide.
Specific examples of the latter drugs include Aldiox, Gutuarnate, L-glutamine, and the like.
これら薬剤は単独で、あるいは試行錯誤的に併用して処
方されているが、どの薬剤のどのような配合が良いかに
ついて予見することはできない。These drugs have been prescribed alone or in combination based on trial and error, but it is impossible to predict which combination of drugs is best.
胃潰瘍は自然治癒する一方、再燃あるいは再発するとい
う臨床的事実がそうした薬剤の配合の検討を非常に困難
なものとし【来た。The clinical fact that while gastric ulcers heal spontaneously, they recur or flare up makes it extremely difficult to consider the combination of such drugs.
本発明者らはヒトの胃潰瘍と形態的にも類似しており、
再燃・再発も認められるラット酢酸潰瘍を用い、潰瘍の
経過な経日的に観察し、また潰瘍の大きさを正確に測定
することの出来る方法を確立した(日本莱学会第102
年会で報告)。この新方法を用い、上記各種薬剤の抗潰
瘍作用を研究したところ、おどろくべきことに、アルジ
オキサとスクラルファートの併用により、潰瘍の治癒の
促進をみるばかりでなく、潰瘍の再燃・再発を抑制する
ことを見出し、医療界で重視している難治性潰瘍の治療
手段となり5る本発明を完成させた。The present inventors found that the ulcer is morphologically similar to human gastric ulcer,
Using rat acetic acid ulcers, which are prone to flare-ups and relapses, we established a method that allows us to observe the progress of the ulcer over time and to accurately measure the size of the ulcer (Japanese Association for Racial Studies No. 102).
(reported at the annual meeting). Using this new method, we studied the anti-ulcer effects of the various drugs mentioned above, and surprisingly found that the combination of ardioxa and sucralfate not only accelerated ulcer healing, but also suppressed ulcer flare-up and recurrence. They discovered this and completed the present invention, which serves as a means of treating intractable ulcers, which is an important topic in the medical world.
アルジオ千すは7ラントインの誘導体であり、化学名は
アルミニウムジヒドロオキシアラントイネートである。Aldiochisu is a derivative of 7-lantoin and its chemical name is aluminum dihydroxyallantoinate.
主な作用は先に述べた防御因子増強型の抗潰瘍作用であ
るが、攻撃因子抑制作用も有しており、抗ペプシン作用
、制酸作用、緩衝作用も有している。そのために胃など
の粘膜に直接的に作用し、速やかに損傷部位を正常な肉
芽組織に成長させるとともに、さらに粘膜上皮の再生促
進、基質微小血管の新生促進、粘液成分の合成分泌促進
作用などを有し広く抗潰瘍剤として臨床的に使われてい
る0スクラルフアートは化学名をショ糖硫酸エステルア
ルミニウム塩といい、抗ペプシン、制酸、胃粘膜保護作
用を有する。Its main action is the aforementioned protective factor-enhancing anti-ulcer action, but it also has an aggressive factor-inhibiting action, as well as anti-pepsin, antacid, and buffering actions. Therefore, it acts directly on the mucous membranes of the stomach and other areas, causing the injured area to quickly grow into normal granulation tissue, and also promotes the regeneration of the mucosal epithelium, the new generation of matrix microvessels, and the synthesis and secretion of mucus components. Osucralfate, which is widely used clinically as an anti-ulcer agent, has the chemical name sucrose sulfate aluminum salt, and has anti-pepsin, antacid, and gastric mucosal protective effects.
臨床的にも潰瘍治癒効果はもとより、疼痛、酸甫。Clinically, it is effective not only for ulcer healing, but also for pain and acid.
状、嘔吐などの自覚症状の改善作用も認められている0
アルジオキサもスクラルファートも抗潰瘍剤とし【比較
的良い薬剤ではあるが、潰瘍を速効的にかつ完全に治癒
させるにはさらに改良が必要であり、スクラルファート
の場合は臨床投与量1日3tをそれ以下に減らすことも
望まれている。It has also been shown to improve subjective symptoms such as nausea and vomiting.
Both ardioxa and sucralfate are considered anti-ulcer agents [although they are relatively good drugs, further improvements are needed to cure ulcers quickly and completely, and in the case of sucralfate, the clinical dose should be lower than 3 tons per day. It is also desired to reduce it.
アルジオ千すとスクラルファートを併用して抗潰瘍作用
を高めたという報告は今までにみられない。There have been no reports to date that the anti-ulcer effect was enhanced by the combination of Algeo Sensu and sucralfate.
本発明者らは種々の抗潰瘍剤の効果を検討した結果、ま
ったく予想外なことにアルジオ千すとスクラルファート
を配合した時に、きわめて着しく消化性潰瘍の治癒効果
を上昇せしめることを見出し本発明を完成させた。すな
わち、本発明の目的は各薬剤単独では稜与量をあげても
とうてい認めることのできないすぐれた相乗効果を示す
アルジオ千すとスクラルファートの配合剤を提供するこ
とにある。As a result of studying the effects of various anti-ulcer agents, the present inventors discovered that, quite unexpectedly, when Aldio Chisu and sucralfate were combined, the healing effect on peptic ulcers was significantly increased. completed. That is, an object of the present invention is to provide a combination preparation of aldio-sulfate and sucralfate that exhibits an excellent synergistic effect that cannot be observed even when the dosage of each drug alone is increased.
このことにより消□化性潰瘍の治癒期間を短縮し、それ
ぞれの薬剤の投与量を減らすことができ、また今までの
薬物療法に抵抗するいわゆる難治性潰瘍に対して有効性
が期待され、手術に移行しなげればならない症例に対し
本発明薬剤は特に有用と考えられる。This makes it possible to shorten the healing period of peptic ulcers and reduce the dosage of each drug.It is also expected to be effective for so-called intractable ulcers that resist conventional drug therapy, and surgery The drug of the present invention is considered to be particularly useful for cases in which patients must progress to
本発明の薬剤の潰瘍治癒効果は完全治癒に約3カ月を要
し、形態的にもヒトの胃潰瘍に類似するといわわるラッ
トの酢酸潰瘍に対する効果で示すことができる。本発明
薬剤を与えた潰瘍ラットは35日で60%の累積治癒率
を示すけれども、アルジオキサ単独では十数パーセント
の治癒で、スクラルファート単独では5%の治癒率であ
る。また潰瘍係数により調べられた潰瘍の縮小速度はア
ルジオキサ単独及びスクラルファート単独よりも有意に
大きい。本発明薬剤がこの実験でこのような治癒率を示
すことはおどろくべき事であり、従来のどんな薬剤でも
観察されていない。この動物実験の結果から、アルジオ
千すとスクラルファートの配合比は1:2〜20が好ま
り、<、その中でも特に好ましいのは1;4〜10 ”
Q アル。The ulcer-healing effect of the drug of the present invention can be demonstrated by its effect on acetic acid ulcers in rats, which require approximately 3 months for complete healing and are morphologically similar to human gastric ulcers. Rats with ulcers given the drug of the present invention showed a cumulative healing rate of 60% in 35 days, but with ardioxa alone the healing rate was more than ten percent, and with sucralfate alone the healing rate was 5%. Also, the rate of ulcer shrinkage, as measured by ulcer index, was significantly greater than that of ardioxa alone and sucralfate alone. It is surprising that the drug of the present invention showed such a cure rate in this experiment, which has never been observed with any conventional drug. From the results of this animal experiment, the blending ratio of Aldio Chisu and sucralfate is preferably 1:2 to 20, and particularly preferred is 1:4 to 10.
Q Al.
本発明者らの動物実験の結果と臨床効果の経験から、本
発明、薬剤の好ましい臨床投与量は難治性潰瘍に使用す
る場合、アルジオキサとして1回1oo1n9程If
、 スクラルファートとして1回10005−
η程度である。一般の消化性潰瘍の場合はこの量の17
4〜172 程度で十分である。Based on the results of animal experiments and the experience of clinical efficacy of the present inventors, the preferred clinical dose of the drug of the present invention is about 101n9 If used as aldioxa once for intractable ulcers.
, Sucralfate is about 10,005-η per dose. For general peptic ulcers, this amount is 17
About 4 to 172 is sufficient.
従って、難治性潰瘍に対する本発明薬剤の臨床投与量は
実施例1で製造した顆粒は大人1回2vずつあるいは実
施例2で製造した錠剤は5錠ずつ、1日3〜4回内服す
る。一般の消化性潰瘍に対する本発明薬剤の臨床投与量
は同様の製剤で、顆粒なら500■〜IP、錠剤なら2
〜3錠を1日3〜4回内服する。 。Therefore, the clinical dosage of the drug of the present invention for intractable ulcers is for adults to take 2 v of the granules produced in Example 1 or 5 tablets of the tablets produced in Example 2, 3 to 4 times a day. The clinical dosage of the drug of the present invention for general peptic ulcers is 500 ~ IP for granules and 2 IP for tablets using the same formulation.
Take ~3 tablets 3-4 times a day. .
本発明薬剤の有効性の証明に酢酸潰瘍ラットの胃内の内
視鏡的観察法を用いた。この方法により、同一個体にお
ける潰瘍の経日的追跡が可能となり潰瘍の縮小経過及び
累積治癒率を求めることができた。Endoscopic observation of the stomachs of rats with acetic acid ulcers was used to prove the effectiveness of the drug of the present invention. This method made it possible to track ulcers in the same individual over time, and to determine the progress of ulcer reduction and cumulative healing rate.
次に本発明薬剤の実験方法、結果について記す。Next, the experimental method and results for the drug of the present invention will be described.
実験方法
1)使用動物:SD系雄性ラット、7週令体重220〜
240f’を用いた(1群15〜20匹)。Experimental method 1) Animals used: SD male rats, 7 weeks old, body weight 220 ~
240f' was used (15 to 20 animals per group).
2)被検薬:アルジオキサ及びスクラルファートの単独
、およびアルジオキサとスクラルファート=6−
を配合したものについて検討した。検体はすべ℃1チア
ラビアゴム溶液に懸濁し、潰瘍作製後3日目観察終了後
より1日2回(9時及び17時)連日経口投与した。な
お、対照群では1チアラビアゴム溶液のみ投与した0
3)潰瘍作製:高木らの方法(ザ・ジャパニーズ・ジャ
ーナル・オブ・ファーマクロジー18巻、9ページ、1
968年)に従った0即ち、ベンドパルビタール麻酔下
に開腹し、胃の幽門腺胃底腺境界部に20%酢酸0.0
5−を注射し、潰瘍を作製した。2) Test drug: Aldioxa and sucralfate alone and a combination of aldioxa and sucralfate (6-) were investigated. The specimens were suspended in a gum thiarabic solution at 1° C. and orally administered twice a day (9:00 and 17:00) from the end of observation on the third day after ulcer creation. In addition, in the control group, only the gum 1 thiarabic solution was administered. 3) Ulcer creation: method of Takagi et al.
968), i.e., the abdomen was opened under bendoparbital anesthesia, and 20% acetic acid 0.0
5- was injected to create an ulcer.
4)観察装置:内視鏡は針状硬性鏡側視型(8E8−1
7178又は818−22178)を、光源はフラッシ
ュ型光輝度光源装置(CLIC−F)を用いた(いずれ
もオリンパス光学工業に、に、製)5)潰瘍の観察二ラ
ットを18時間絶食し、エーテル吸入麻酔下に硬性鏡及
びポリエチレンチューブを通して約15−の空気を注入
し、胃を膨らませ、チコーーブ抜去後胃内観察を行なっ
た0観察は潰瘍作製後3 、10,20,35.l1t
O,70日目に行なった◎6)潰瘍係数:内視鏡で観察
した潰瘍の長径(U Iz)と短径(UI a)の積と
して、潰瘍係数(UI )を求め潰瘍の大きさの指標と
した。4) Observation device: The endoscope is a needle-shaped rigid scope side-viewing type (8E8-1
7178 or 818-22178), and the light source was a flash-type luminance light source device (CLIC-F) (both manufactured by Olympus Optical Industries, Ltd.) 5) Observation of ulcers Two rats were fasted for 18 hours, and ether Approximately 15 mm of air was injected through a rigid scope and a polyethylene tube under inhalation anesthesia to inflate the stomach, and after the Chico tube was removed, intragastric observations were performed. l1t
◎6) Ulcer coefficient: Calculate the ulcer coefficient (UI) as the product of the long axis (U Iz) and the short axis (UI a) of the ulcer observed with an endoscope and calculate the size of the ulcer. It was used as an indicator.
Ul = UI、!XUIs
7)潰瘍治癒率:内視鏡観察において、潰瘍底に白苔が
なく、かつ辺縁粘膜との境界が不鮮明なもの、あるいは
周辺粘膜と区別がなく、潰瘍部が不明となったものを治
癒と判定した。治癒率は観察例数に対する治癒例数の比
率を累積値情で示した。Ul=UI,! XUIs 7) Ulcer healing rate: In endoscopic observation, ulcers with no white moss at the base and the border with the marginal mucosa are unclear, or where there is no distinction from the surrounding mucosa and the ulcer area is unclear. It was determined that the patient was cured. The cure rate was expressed as a cumulative ratio of the number of cured cases to the number of observed cases.
結果
1)潰瘍係数の経日変動:各群のUI値の経日変動を表
1に示す0フルジオ千す群は対照群に比べ20、50.
70日目で有意に小さなUI値を示し、フルジオ千すに
より著しく潰瘍の縮小が促進される。スクラルファート
群においては70日目においてのみ有意に小さなUI値
を示した〇一方、配合群は20゜35、50.70日目
において対照群に対し有意差が認められ、更に35.5
0.70日目のUI値は71レジオ千す及びスクラルフ
ァート嚇独群に比べても有意に小さなtnllであり、
両薬剤配合により、潰瘍の縮小作用が著しく先進された
。Results 1) Daily fluctuations in ulcer index: Table 1 shows the daily fluctuations in UI values for each group.
On day 70, the UI value was significantly lower, and the reduction of the ulcer was significantly promoted by Flugeo Sensu. The sucralfate group showed a significantly smaller UI value only on the 70th day.On the other hand, the combination group showed a significant difference from the control group on the 20.35 and 50.70 days, and the UI value was 35.5.
0. The UI value on day 70 was significantly smaller than the 71 Regio Sensu and Sucralfate group,
The combination of both drugs significantly improved the ulcer reduction effect.
2)治癒率:第1図に示されるように対照群は35日目
において、20例中1例の治癒が認められたが、その後
、治癒例の増加は認められなかった。2) Cure rate: As shown in Figure 1, 1 out of 20 cases in the control group was cured on the 35th day, but no increase in the number of cured cases was observed thereafter.
アルジオキサ群、スクラルファート群の初発治癒例も3
5日目で認められるが、対照群とは異なり、漸次、治癒
率は増加し、70日目で30%程度の治癒率を示した〇
一方、配合群では20日目で初発治癒例を認め、その後
、急激に治癒率は増大し、70日目で80%以上の治癒
率を示した0即ち、アルジオ千すとスクラルファートと
の配合により、治癒期間の短縮及び治癒率の著しい向上
が認められた。There were also 3 cases of initial recovery in the ardioxa group and sucralfate group.
It was observed on the 5th day, but unlike the control group, the cure rate gradually increased, and showed a cure rate of about 30% on the 70th day.On the other hand, in the combination group, the initial cure rate was reached on the 20th day. After that, the cure rate increased rapidly, and showed a cure rate of over 80% on the 70th day. In other words, the combination of Algeo Sensu and sucralfate shortened the healing period and significantly improved the cure rate. It was done.
なお、いずれの群も毒性はみられなかった。即ち、本発
明の配合剤は67日間連続投与しても毒性はみられず低
毒性の薬剤である。Furthermore, no toxicity was observed in either group. That is, the combination drug of the present invention shows no toxicity even after continuous administration for 67 days, and is a low-toxicity drug.
次に本発明を実施例にてさらに詳細に説明する。Next, the present invention will be explained in more detail with reference to Examples.
実施例1
顆粒剤12中の処方例
アルジオキサ 50■
スクラルファ−) 500■乳
糖 150〜結晶
セルロース 3071fトウモロコシデ
ンプン 240■デキストリン
20■カルボ千ジメチルセルロースカルシウム
lO■上記の成分をその割合になるように量り、
混和し、「日局士」製剤総則の顆粒剤の製法に準じて顆
粒剤とした。Example 1 Prescription example in granule 12 Aldioxa 50■ Sucralfa) 500■ Milk
Sugar 150~Crystalline cellulose 3071f Corn starch 240■Dextrin
20 ■ Carbo-thousand dimethylcellulose calcium
lO ■Weigh the above ingredients to the proportions,
The mixture was mixed and made into granules according to the manufacturing method for granules in the General Rules for Preparations of ``Nichikyoshi''.
実施例2
錠剤1錠中の処方例
アルジオ千サ 20〜スクラルフアー
ト 80■メタケイ酸アルミン酸マグネ
シウム 58■トウモロコシデンプン
50m9デ千ストリン 1
0〜ステアリン酸マグネシウム 2m9上記
の成分をその割合になるように量り、混和し、「日局士
」製剤総則の錠剤の製法に準じ錠剤とした◇Example 2 Prescription example in 1 tablet Ardio Sensa 20 ~ Sukralfate 80 ■ Magnesium aluminate metasilicate 58 ■ Corn starch 50 m9 De Sensutra 1
0 ~ Magnesium stearate 2m9 Weigh the above ingredients to the appropriate proportions, mix them, and make tablets according to the tablet manufacturing method in the "Japanese Pharmacist" general rules for preparations◇
第1図はラット酢酸潰瘍に対する各種抗潰瘍剤の治癒効
果を示したものである。縦軸は累積治癒率φ)を示し、
横軸は日数を示す。
)−4は対照群を、○−−−○はアルジオキサ群を、D
−=−0はスクラルファート群を、■・・・・・・・・
−一はフルジオ千す+スクラルファート配合群をそれぞ
れ示すO
特許出願人
グレラン製薬株式会社
代理人
柊 木 峯 治
茸i図
(%)
第1頁の続き
0発 明 者 内田勝幸
神奈川県高座郡寒用町−之宮13
2
0発 明 者 大林繁夫
東京都世田谷区世田谷1−3−FIG. 1 shows the healing effects of various anti-ulcer agents on rat acetic acid ulcers. The vertical axis shows the cumulative healing rate φ),
The horizontal axis shows the number of days. )-4 is the control group, ○---○ is the aldioxa group, D
-=-0 indicates sucralfate group, ■・・・・・・・・・
-1 indicates the Fludiosensu + Sucralfate combination group O Patent Applicant Grelan Pharmaceutical Co., Ltd. Agent Haru Hiragi Ki Mine Figure (%) Continued from page 1 0 Inventor Katsuyuki Uchida Kanyo, Koza District, Kanagawa Prefecture Town-nomiya 13 20 Inventor Shigeo Obayashi 1-3 Setagaya, Setagaya-ku, Tokyo
Claims (1)
比で配合された消化性潰瘍治療配合剤。A combination drug for treating peptic ulcers containing ardioxa and sucralfate in a weight ratio of 1=2 to 1.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP9141382A JPS58208233A (en) | 1982-05-31 | 1982-05-31 | Formulating ingredient for treating peptic ulcer |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP9141382A JPS58208233A (en) | 1982-05-31 | 1982-05-31 | Formulating ingredient for treating peptic ulcer |
Publications (1)
Publication Number | Publication Date |
---|---|
JPS58208233A true JPS58208233A (en) | 1983-12-03 |
Family
ID=14025689
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP9141382A Pending JPS58208233A (en) | 1982-05-31 | 1982-05-31 | Formulating ingredient for treating peptic ulcer |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS58208233A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0331385A2 (en) * | 1988-03-02 | 1989-09-06 | Chugai Pharmaceutical Co., Ltd. | Aqueous suspension of sucralfate |
WO1996025158A1 (en) * | 1995-02-16 | 1996-08-22 | Yamanouchi Pharmaceutical Co., Ltd. | Medicinal composition containing azulene derivative and process for producing the same |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5220525A (en) * | 1975-08-09 | 1977-02-16 | Nippon Soken Inc | Stea belt take-up means |
JPS5677295A (en) * | 1979-09-14 | 1981-06-25 | Maruko Seiyaku Kk | Co-precipitation substance of aluminum of sucrose sulfate and dihydroxy aluminum allantoinate |
JPS5677294A (en) * | 1979-08-28 | 1981-06-25 | Maruko Seiyaku Kk | Aluminum compound substance of sucrose sulfate and dihydroxy aluminum allantoinate |
-
1982
- 1982-05-31 JP JP9141382A patent/JPS58208233A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5220525A (en) * | 1975-08-09 | 1977-02-16 | Nippon Soken Inc | Stea belt take-up means |
JPS5677294A (en) * | 1979-08-28 | 1981-06-25 | Maruko Seiyaku Kk | Aluminum compound substance of sucrose sulfate and dihydroxy aluminum allantoinate |
JPS5677295A (en) * | 1979-09-14 | 1981-06-25 | Maruko Seiyaku Kk | Co-precipitation substance of aluminum of sucrose sulfate and dihydroxy aluminum allantoinate |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0331385A2 (en) * | 1988-03-02 | 1989-09-06 | Chugai Pharmaceutical Co., Ltd. | Aqueous suspension of sucralfate |
WO1996025158A1 (en) * | 1995-02-16 | 1996-08-22 | Yamanouchi Pharmaceutical Co., Ltd. | Medicinal composition containing azulene derivative and process for producing the same |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lam et al. | Prostaglandin E 1 (misoprostol) overcomes the adverse effect of chronic cigarette smoking on duodenal ulcer healing | |
JPH0948728A (en) | Antipyretic and analgesic agent | |
JP2005247874A (en) | Process for preparation of oral solid dosage form containing diclofenac | |
KR100238565B1 (en) | Ingestible pharmaceutical compositions for treating upper gastrointestinal tract distress | |
Hui et al. | Chronic antral gastritis in duodenal ulcer: Natural history and treatment with prostaglandin E1 | |
US2868693A (en) | Peptic ulcer-treating compositions containing glutamine | |
JPS58208233A (en) | Formulating ingredient for treating peptic ulcer | |
US3092548A (en) | Method of treating peptic ulcers with pantothenic acid | |
DE2820900A1 (en) | MEDICINAL PRODUCTS FOR THE TREATMENT OF GASTRITIDES, GASTRODUODENITIDES AND GASTRODUODENAL ULCERA | |
WO1998001146A1 (en) | Preventives/remedies for stomatitis | |
JP2000219625A (en) | Medicinal composition | |
JP2002265354A (en) | Anti-helicobacter pylori agent composition | |
RU2809024C2 (en) | Montelukast for treatment of erosive osteoarthritis of the hand | |
JPS58208220A (en) | Remedy for peptic ulcer | |
WO2017211182A1 (en) | Pharmaceutical composition for preventing and treating inflammatory disease | |
Zucker et al. | Bertram W. Sippy and ulcer disease therapy | |
DE69736955T2 (en) | METHOD AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF SODBRENNES | |
Ryan et al. | Mucosal irritant potential of a potassium‐sparing diuretic and of wax‐matrix potassium chloride | |
US10973850B2 (en) | Composition comprising tricalcium phosphate and gelatin for use in a method for the treatment of dyspepsia and related disorders | |
JP2003342186A (en) | Oral liquid formulation composition for rhinitis | |
KR0130427B1 (en) | Complexed antiulcer compositions | |
JPH09512262A (en) | H. Use of spiramycin for the treatment of gastrointestinal disorders caused by pylori | |
RU1635329C (en) | Medicinal composition for destroying pyloric campilobacterial organisms and method of sanitation of mucous membrane of stomach | |
Huber et al. | An Unusual Case of Screw-worms in the Nose and Nasal Accessory Sinuses | |
Semple | Report on Materia Medica and Therapeutics |